Close
Smartlab Europe
Achema middle east

BioPharma

CRISPR and Gene Editing: Next-Gen Manufacturing Impacts

The pharmaceutical and biotechnology industries are experiencing a profound technological revolution driven by CRISPR-Cas9 and emerging gene editing technologies that fundamentally alter how therapeutic agents are developed and manufactured. Gene editing pharma manufacturing represents far more than incremental improvement...

Precision Medicine Manufacturing: From Large-Scale to Patient-Centric Production

The pharmaceutical industry is experiencing a fundamental shift away from the traditional “blockbuster drug” model toward increasingly sophisticated precision medicine manufacturing strategies that prioritize individual patient needs over mass-market volume. This transformation represents far more than a simple adjustment...

In Silico and Virtual Trials: Revolutionizing Drug Development

Drug development is entering an era of radical transformation as pharmaceutical companies embrace virtual trials and in silico methodologies to reimagine the clinical research process. These digital-first strategies tap into computational models, artificial intelligence, and patient-specific simulations to address...

AI-Enabled Supply Chain Resilience in Pharmaceutical Manufacturing

Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In today’s environment, pharmaceutical supply chain resilience depends not only on physical infrastructure and traditional logistics but...

CDMO Market for AAV Therapies to Hit $2.566 Billion By 2033

With a focus on Adeno-Associated Virus (AAV), the worldwide market for Contract Development and Manufacturing Organizations (CDMMOs) that biomanufacture cell and gene therapies has shown spectacular development, estimated to reach $0.2313 billion in 2022. Based on projections, this market...

Pharmaceutical CMO Market is Set for a 7.29% CAGR by 2028

It is projected that the market for pharmaceutical contract manufacturing organizations (CMOs) would expand at a compound annual growth rate (CAGR) of 7.29 percent until the year 2028. This rise may be ascribed to the expanded pharmaceutical industry, which...

Global CDMO Market for Cell and Gene Therapy Expands Rapidly

During the period of time from 2023 to 2029, the global market for cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is projected to grow at a compound annual growth rate (CAGR) of 17.5%. In 2022,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »